Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401107 | 0.89 | TACR1 (0.42) | TACR1F10F2PLAU | |
| SCHEMBL1401110 | 0.89 | TACR1 (0.42) | TACR1F10F2PLAU | |
| SCHEMBL12188654 | 0.83 | TACR1 (0.40) | TACR1F10PLAU | |
| SCHEMBL12240870 | 0.80 | GHSR (0.39) | TACR1F10OPRD1PLAU | |
| SCHEMBL1401188 | 0.80 | OPRD1 (0.44) | TACR1F10OPRD1F2PLAU | |
| SCHEMBL12188653 | 0.80 | GHSR (0.51) | TACR1OPRD1 | |
| SCHEMBL1401201 | 0.79 | HPGD (0.47) | — | |
| SCHEMBL7897790 | 0.79 | HPGD (0.47) | — | |
| SCHEMBL1401204 | 0.79 | HPGD (0.47) | — | |
| SCHEMBL1401075 | 0.75 | TACR1 (0.47) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576062-B2 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | NOVO NORDISK A/S (DK) | 2009-08-18 | — | — | US | disclosed |